Neurodegeneration in AD is currently captured in-vivo by Fluorodeoxyglucose (FDG) PET hypometabolism, CSF total-tau, and atrophy on magnetic resonance imaging (MRI). The gene discussed is MAPT; the disease is Alzheimer disease.